INC Research Ranked "Top CRO to Work With" Among Large Global CROs for a Second Straight Time in Biannual CenterWatch Survey

RALEIGH, N.C., April 1, 2015 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, is ranked "Top CRO to Work With" among large global CROs in the biannual CenterWatch Global Investigative Site Relationship Survey. Results of the 2015 survey were published earlier today by CenterWatch, the leading provider of global clinical trials information. INC Research also received the top ranking in CenterWatch's most recent global investigative site relationship survey completed in 2013 and is the only CRO to rank consistently among the top three CROs in all seven CenterWatch site relationship surveys conducted since 2007.

"INC Research's ranking is a direct reflection of our continued dedication to supporting clinical research sites globally, leveraging their insights to improve drug development and providing optimal support to ensure their success," says Chief Executive Officer Jamie Macdonald. "Our therapeutically aligned teams understand the pain points for sites and are able to work with them more effectively to ease these challenges and improve clinical development. Through many years of working with sites, our team has focused on growing deeper site relationships and making sites feel fully supported on every trial."

INC Research's top ranking in the CenterWatch survey reflects the Company's continued and significant focus on site relationships to enhance its delivery of global clinical development programs for biopharmaceutical customers worldwide. INC Research is a Global Impact Partner and Circle of Sustainability Sponsor (the highest level of partnership) with the Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites. INC is the first and only CRO to sponsor SCRS scholarships to provide sites across the globe the benefit of training and mentoring gained through SCRS membership. The Company is also the first and only CRO to utilize Site Advocacy Groups, a new forum providing valuable perspectives from sites earlier in the clinical trials process leading to greater predictability in performance and improved site sustainability. INC is committed to recognizing the contributions of its site partners globally through programs such as the INC Research Clinical Research Site Award, through which more than 100 awards were given in 2014.

"Clinical research sites are critical to the drug development process and it is important we continue to recognize their contributions and provide the support they need to be successful," says Clare Grace, Vice President, Site and Patient Access. "INC has long valued quality site relationships and fosters a collaborative approach to activities and deliverables. We work closely with sponsors and sites to develop a common understanding of expectations and standardize processes to enhance research and reach shared goals. Ultimately, we all work together to improve the lives of patients through medical research."

CenterWatch's 2015 Global Investigative Site Relationship Survey was conducted online between October 2014 and January 2015 and included participation from principal investigators, sub-investigators and study coordinators at more than 1,900 sites. INC Research's combined excellent/good ratings and average excellent ratings in the 2015 CenterWatch survey were higher compared to 2013 survey results, a testament to the Company's commitment to continuous improvement under its Trusted Process® driving engagement with sites as key stakeholders in the clinical trials process. Rankings in the CenterWatch survey are based on a combination of two measures: an overall relationship quality rating based on "excellent" scores from sites, and the frequency with which companies placed among the top-three rated CROs across all relationship attributes measured.

About INC Research

INC Research (Nasdaq:INCR) is a leading global contract research organization (CRO) providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industry. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. The Company was ranked the "Top CRO to Work With" among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, N.C., with operations across six continents and experience spanning more than 100 countries. For more information, please visit and connect with us on LinkedIn and Twitter @inc_research.

CONTACT: Investors: Ronnie Speight, +1 919 745 2745 Media: Lee Kennedy, +1 919 666 0772Source:INC Research